Like the Eddie Aikau Big Wave Invitational, the Da Hui Backdoor Shootout has weather-dependent standards to meet its prestigious legacy. But unlike The Eddie, this beloved local event has the freedom ...
ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its ...
Kala Bio, Inc. (NASDAQ:KALA) announced Monday that its Audit Committee approved the dismissal of Deloitte & Touche LLP as the company’s independent registered public accounting firm, effective the ...
ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) ("KALA” or the "Company”), today announced the closing of its previously announced registered direct offering priced at ...
KALA BIO, Inc. (NASDAQ: KALA) shares jumped 22.16% to $1.13 in after-hours trading on Wednesday. Check out the current price of KALA stock here. Securities and Exchange Commission filings indicate ...
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an ...
Kala Bio shares surged after the biopharmaceutical company said it had named David Lazar as chief executive and board chair, following the investor's purchase of $6 million in stock. Kala shares were ...
Rashtrapati Nilayam, Bolarum, is set to host the second edition of the Bharatiya Kala Mahotsav from November 22 to 30, bringing together the cultural, artistic and culinary heritage of India’s western ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Arlington biotech has been ...
Kala Bio said it laid off most of its employees after receiving notice that its lender, Oxford Finance, intends to foreclose on all of its remaining assets. The move follows the biotech company's ...
Kala Bio, Inc. (NASDAQ:KALA), a biotech company with a market capitalization of $10.74 million and showing significant stock volatility, announced it received a written notice of default from Oxford ...
Kala Bio will stop developing its experimental treatment for a type of eye condition after it failed to meet the main goal in a mid-stage study, sending the drug developer's shares down 93% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results